Traditional mRNA-based approaches have shown immense potential, particularly in rapid vaccine deployment and gene replacement therapies. Building upon this foundation, self-amplifying RNA (saRNA) ...

An increase in research and development (R&D) activities in myotonic dystrophy is expected to drive market growth by ...

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

PYC Therapeutics (ASX:PYC) has announced plans to advance its investigational drug candidate, PYC-003, into human clinical ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on ...